PARSHALL B LYNNE 4

What Happened
B. Lynne Parshall, a director of Cytokinetics (CYTK), reported the sale of 5,000 common shares on June 1, 2026. The reported price was $74.08 per share, for total proceeds of $370,400. The Form 4 lists the transaction as an "open market or private sale" (code S), indicating a sale rather than a purchase or option exercise.

Key Details

• Transaction date: 2026-06-01
• Shares sold: 5,000 at $74.08 per share
• Gross proceeds: $370,400
• Transaction type/code: Sale (S) — listed as "open market or private sale" on the Form 4
• Shares owned after transaction: Not included in the provided extract; check the full Form 4 filing for post-transaction holdings
• Footnotes/plans: No 10b5-1 plan, tax withholding, or other footnotes were provided in the information supplied
• Filing timeliness: Report filed the same day (2026-06-01), indicating a timely Form 4 submission (accession: 0001061983-26-000064)

Context
This was a straightforward sale by a company director. Sales by insiders can be routine (liquidity, portfolio rebalancing, taxes) and do not, by themselves, indicate a change in the company’s fundamentals. Retail investors wanting to interpret insider activity should look for patterns (multiple insiders selling, large concurrent sales, or insider buys) and review the complete Form 4 for ownership after the trade.